Loading clinical trials...
Loading clinical trials...
Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines: Adenovirus-vectored Vaccine Versus mRNA Vaccine
Conditions
Interventions
This is observational study
Locations
1
South Korea
Koera University Guro Hospital
Seoul, South Korea
Start Date
February 25, 2021
Primary Completion Date
July 16, 2021
Completion Date
December 31, 2023
Last Updated
December 9, 2021
NCT07221162
NCT06082518
NCT06631287
NCT06679140
NCT06417762
NCT03830320
Lead Sponsor
Korea University Guro Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions